In DepthBiomedical Policy

U.S. House reveals ambitious biomedical innovation plan

See allHide authors and affiliations

Science  06 Feb 2015:
Vol. 347, Issue 6222, pp. 594-595
DOI: 10.1126/science.347.6222.594

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Since last April, a bipartisan team in the U.S. House of Representatives has led a high-profile initiative to speed the development of new medical treatments. Last week, the initiative bore its first fruit: a sweeping draft proposal released by Energy and Commerce Committee Chair Fred Upton (R–MI) that would overhaul many policies at the National Institutes of Health and the Food and Drug Administration. But Upton's draft had a bumpy rollout. His partner in the initiative, Diana DeGette (D–CO), announced that she did not endorse it. And although the document is attracting praise from many industry and research advocacy groups, some are concerned that it neglects basic research funding while extending overly generous terms to drug companies.

  • * With reporting by Jocelyn Kaiser.

View Full Text

Stay Connected to Science